subcutaneous administration

Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial

1 month ago talkbio0Tagged BCG Vaccine, Event-Free Survival, Inhibitor, Invasive, Malignant neoplasm of urinary bladder, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Overall Survival, PDCD1 gene, Phase 3 CREST trial, Sasanlimab, subcutaneous administration

Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration

Bristol Myers Squibb Marks Milestone with FDA Approval of Subcutaneous Opdivo Qvantig

5 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, immuno-oncology, Inhibitor, Myers, PDCD1 gene, squibb, subcutaneous administration, United States Food and Drug Administration

Bristol Myers Squibb, Opdivo, subcutaneous administration, FDA approval, cancer treatment, immuno-oncology, PD-1 inhibitor.

Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options

9 months ago talkbio0Tagged Approved, Enhanze Drug Delivery, Halozyme, Hybreza, Immunotherapy for cancer, Inhibitor, PD-L1, Roche (company), subcutaneous administration, Tecentriq, Technology, United States Food and Drug Administration

Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology

RYBREVANT: A Breakthrough in Lung Cancer Treatment

1 year ago talkbio0Tagged Epidermal Growth Factor Receptor, Infusion-Related Reaction, intravenous administration, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous administration, Survival Rate

RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)